2928067-26-7

Nilvadipine-d4 is intended for use as an internal standard for the quantification of nilvadipine (Item No. 21243) by GC- or LC-MS. Nilvadipine is a dihydropyridine L-type calcium channel blocker.1 It is selective for L-type over N-, P/Q-, and R-type calcium channels at 10 μM. Nilvadipine (10 mg/kg per day, p.o.) inhibits increases in systolic blood pressure induced by chronic intravenous infusion of the peptide vasoconstrictor endothelin in rats.2 It decreases cortical and hippocampal amyloid-β burden in the APPsw (Tg2576) and PS1/APPsw transgenic mouse models of Alzheimer's disease when administered at a dose of 0.03% (w/w) in the diet for 17 and 10 months, respectively.3 Nilvadipine (3.2 mg/kg, s.c.) reduces infarct volume in a rat model of focal cerebral ischemia induced by middle cerebral artery occlusion (MCAO).4WARNING This product is not for human or veterinary use.

[1] T FURUKAWA. Selectivities of dihydropyridine derivatives in blocking Ca(2+) channel subtypes expressed in Xenopus oocytes.[J]. Journal of Pharmacology and Experimental Therapeutics, 1999, 291 2: 464-473.
[2] M YASUJIMA. Antihypertensive effect of captopril and enalapril in endothelin-infused rats.[J]. Tohoku Journal of Experimental Medicine, 1991, 163 3: 219-227. DOI: 10.1620/tjem.163.219
[3] DANIEL PARIS. Selective antihypertensive dihydropyridines lower Aβ accumulation by targeting both the production and the clearance of Aβ across the blood-brain barrier.[J]. Molecular Medicine, 2011, 17 3-4: 149-162. DOI: 10.2119/molmed.2010.00180
[4] S KAWAMURA. Effects of a Ca2+ entry blocker (nilvadipine) on acute focal cerebral ischemia in rats.[J]. Experimental Brain Research, 1991, 83 2: 434-438. DOI: 10.1007/bf00231169